United States v. Chykeetra Maltbia, M.D.

CourtCourt of Appeals for the Eleventh Circuit
DecidedFebruary 9, 2023
Docket21-14446
StatusUnpublished

This text of United States v. Chykeetra Maltbia, M.D. (United States v. Chykeetra Maltbia, M.D.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Chykeetra Maltbia, M.D., (11th Cir. 2023).

Opinion

USCA11 Case: 21-14446 Document: 37-1 Date Filed: 02/09/2023 Page: 1 of 18

[DO NOT PUBLISH] In the United States Court of Appeals For the Eleventh Circuit

____________________

No. 21-14446 Non-Argument Calendar ____________________

UNITED STATES OF AMERICA, Plaintiff-Appellee, versus CHYKEETRA MALTBIA, M.D.,

Defendant-Appellant.

Appeal from the United States District Court for the Southern District of Alabama D.C. Docket No. 1:19-cr-00209-JB-MU-1 ____________________ USCA11 Case: 21-14446 Document: 37-1 Date Filed: 02/09/2023 Page: 2 of 18

2 Opinion of the Court 21-14446

Before NEWSOM, BRANCH, and GRANT, Circuit Judges. PER CURIAM: Dr. Chykeetra Shinnyette Maltbia appeals her convictions for possession with intent to distribute controlled substances. She asserts that the district court erred for three reasons. First, she argues that the district court’s exclusion of “good patient care” evidence deprived her of the right to present a complete defense in violation of the Fifth and Sixth Amendments. Second, she argues that the district court erred by not giving the jury a “good faith” instruction. Third, she contends for the first time on appeal that the district court should have instructed the jury that the government is required to prove that Maltbia issued prescriptions without a legitimate medical purpose and was acting outside the usual course of medical practice. Because Maltbia is not entitled to relief on any of her claims, we affirm her convictions. We address each enumeration of error in turn. I. Background In February 2020, a grand jury indicted Maltbia with one count of conspiracy to possess with intent to distribute controlled substances in violation of 21 U.S.C. § 846 (Count One); sixteen counts of possession with intent to distribute controlled substances in violation of 21 U.S.C. § 841(a)(1) (Counts Two through Seventeen); and eighteen counts of healthcare fraud in violation of USCA11 Case: 21-14446 Document: 37-1 Date Filed: 02/09/2023 Page: 3 of 18

21-14446 Opinion of the Court 3

18 U.S.C. § 1347 (Counts Eighteen through Thirty-Five). 1 Maltbia pleaded not guilty on all counts, and the district court set the case for trial. Before trial, the government moved to dismiss the healthcare fraud claims, and the court granted the motion. Maltbia is a physician who owned and operated a medical clinic in Mobile, Alabama. At trial, a special agent with the United States Drug Enforcement Administration (“DEA”) testified that he became familiar with Maltbia’s clinic through an investigation into several individuals for selling “oxycodone 30” prescription pills. 2 He discovered that the individuals selling oxycodone 30 were Maltbia’s patients and observed them at Maltbia’s clinic. After searching Maltbia’s clinic and the electronic data stored on her computers pursuant to a search warrant, he learned that Maltbia regularly prescribed controlled substances to her patients— including oxycodone 30. Further investigation revealed that Maltbia had already signed prescriptions for patients that she was scheduled to see later in the day; that Maltbia charged her patients $300 per visit; that Maltbia’s patients “mainly” paid in cash or by credit card; and that Maltbia had issued prescriptions to patients while she was out-of-state on multiple occasions. A DEA

1 In August 2019, a grand jury indicted Maltbia with five violations of 21 U.S.C. § 841(a)(1). Later that fall, Maltbia pleaded not guilty on all counts. A grand jury then returned a superseding indictment in February 2020. 2 Testimony at trial explained that oxycodone 30 refers to the dosage of oxycodone (30 milligrams) and that oxycodone 30 has the “highest street value” for oxycodone. USCA11 Case: 21-14446 Document: 37-1 Date Filed: 02/09/2023 Page: 4 of 18

4 Opinion of the Court 21-14446

intelligence analyst testified that 58.7% of Maltbia’s patients received at least one prescription of oxycodone 30. And the government’s expert witness concluded that Maltbia prescribed opioids without properly assessing patients and that she falsified medical records. The jury found Maltbia guilty on Count Two and Counts Four through Seventeen. 3 After denying Maltbia’s motion for new trial, the district court sentenced her to five years’ probation for each count, with each probationary term to run concurrently, and ordered Maltbia to pay a $50,000.00 fine. Maltbia timely appealed. II. Discussion a. Whether the district court erred by excluding “favorable patient testimony” First, Maltbia argues that the district court denied her the right to present a complete defense in violation of the Fifth and Sixth Amendments to the Constitution by excluding “favorable patient testimony.” We disagree. Prior to trial, the government filed a motion in limine to exclude testimony from Maltbia’s “good patient[s]” during opening statements or “during trial without first making an argument

3 Maltbia moved for acquittal during trial and at the close of evidence, and the district court granted her motions in part and dismissed Counts One and Three. USCA11 Case: 21-14446 Document: 37-1 Date Filed: 02/09/2023 Page: 5 of 18

21-14446 Opinion of the Court 5

outside the jury’s presence.” The government explained that a common “defense tactic in trials where the defendant is a medical professional is for the defendant to attempt to call ‘good patient’ witnesses—i.e., patients who will testify that they received proper medical care from the defendant.” The government argued that “[w]hile such testimony might appear to be relevant at first blush, ‘good patient’ testimony is actually impermissible character evidence.” Maltbia opposed the motion, arguing that excluding evidence of good patient care would deprive her of a fair trial and her right to present a full defense under the Fifth and Sixth Amendments. After a hearing, the district court granted the government’s motion and stated that “[a]ny request for the [c]ourt to revisit the issue of admissibility at trial shall occur outside the presence of the jury.” “Whether the exclusion of evidence violated a constitutional guarantee is a legal question reviewed de novo.” United States v. Sarras, 575 F.3d 1191, 1209 n.24 (11th Cir. 2009). And “[i]n assessing a defendant’s claims under the Fifth and Sixth Amendments to call witnesses in her defense, . . . [w]e first examine whether [the] right was actually violated, [and] then turn to whether [the] error was harmless.” United States v. Hurn, 368 F.3d 1359, 1362–63 (11th Cir. 2004) (quotation omitted). USCA11 Case: 21-14446 Document: 37-1 Date Filed: 02/09/2023 Page: 6 of 18

6 Opinion of the Court 21-14446

“The Constitution guarantees criminal defendants a meaningful opportunity to present a complete defense.” United States v. Akwuba, 7 F.4th 1299, 1312 (11th Cir. 2021) (quotation omitted). But the right to present a complete defense is not absolute; rather, it is subject to reasonable restrictions. Id. “[S]tate and federal rulemakers have broad latitude under the Constitution to establish rules excluding evidence from criminal trials.” United States v. Mitrovic, 890 F.3d 1217, 1221 (11th Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. David Wayne Monroe
353 F.3d 1346 (Eleventh Circuit, 2003)
United States v. Patrice Daliberti Hurn
368 F.3d 1359 (Eleventh Circuit, 2004)
United States v. Scheffer
523 U.S. 303 (Supreme Court, 1998)
United States v. Tobin
676 F.3d 1264 (Eleventh Circuit, 2012)
Henderson v. United States
133 S. Ct. 1121 (Supreme Court, 2013)
United States v. Jack Kelly Joseph
709 F.3d 1082 (Eleventh Circuit, 2013)
Edward Dell v. United States
710 F.3d 1267 (Eleventh Circuit, 2013)
United States v. Sarras
575 F.3d 1191 (Eleventh Circuit, 2009)
United States v. James Dale Little
864 F.3d 1283 (Eleventh Circuit, 2017)
United States v. Mladen Mitrovic
890 F.3d 1217 (Eleventh Circuit, 2018)
United States v. Geovanys Guevara
894 F.3d 1301 (Eleventh Circuit, 2018)
United States v. Fernando Sanchez, Jr.
940 F.3d 526 (Eleventh Circuit, 2019)
United States v. Dan Reed
941 F.3d 1018 (Eleventh Circuit, 2019)
United States v. James Innocent
977 F.3d 1077 (Eleventh Circuit, 2020)
United States v. Arman Abovyan
988 F.3d 1288 (Eleventh Circuit, 2021)
United States v. Lillian Akwuba
7 F.4th 1299 (Eleventh Circuit, 2021)
United States v. Rodriguez
398 F.3d 1291 (Eleventh Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Chykeetra Maltbia, M.D., Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-chykeetra-maltbia-md-ca11-2023.